EUCTR2005-002427-14-GB进行中（未招募）1 期
A Randomised Placebo-Controlled Phase II Study of Continuous Maintenance Treatment with BIBF 1120 Following Chemotherapy in Patients with Relapsed Ovarian Cancer -
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 89
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •1) Female patients with histologically confirmed advanced ovarian carcinoma, fallopian tube carcinoma or primary peritoneal cancer of serous type with recurrent disease and who responded to 2nd, 3rd or 4th line chemotherapy. Response is defined as either a confirmed decline in CA125 of at least 50% from the pre-treatment value or an Objective Response, i.e. a Partial Response (PR) or Complete Response (CR) according to the RECIST criteria in patients with measurable disease.
- •2) Treatment-free interval of = 12 months since commencing prior treatment regimen for relapsed ovarian cancer.
- •3) Full recovery from all therapy related toxicities of previous chemotherapy and or radiotherapy or recovery in as much as no further improvement may be expected by the investigator.
- •4) Age = 18 years.
- •5) Life expectancy of at least 3 months.
- •6) ECOG Performance Score < 2.
- •7) Adequate hepatic function: total bilirubin 26µmol/L, ALT and/or AST = 1.5x upper limit of normal (ULN). INR, Prothrombin time (PT) and partial thromboplastin time (PTT): maximum 50% deviation from normal limits.
- •8) Adequate renal function: serum creatinine = 1.5 x ULN.
- •9) Absolute neutrophil count (ANC) = 1.500/µl, Platelets = 100.000/µl,
- •Haemoglobin = 9.0 g/dl.
- •10) Written informed consent consistent with ICH-GCP guidelines.
- •11) Minimum time elapsed since last chemotherapy (including hormonal treatment other than Hormone Replacement Therapy [HRT]) or immunotherapy and the first administration of BIBF 1120 must be more than 4 but less than 8 weeks.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1) Serious illness or concomitant non-oncological disease such as neurologic, psychiatric, infectious disease or active ulcers (gastro-intestinal tract, skin) or laboratory abnormality that may increase the risk associated with study participation or study drug administration and in the judgment of the investigator would make the patient inappropriate for entry into the study.
- •2) Major injuries and/or surgery within past 4 weeks with incomplete wound healing or bone fracture and planned surgical procedures during the study period.
- •3) Hypersensitivity to BIBF 1120 or the excipients of the study drug.
- •4) Significant cardiovascular diseases (i.e. uncontrolled hypertension, unstable angina, history of infarction within past 9 months, congestive heart failure > NYHA II).
- •5) History of haemorrhagic or thrombotic event in the past 12 months. Known inherited predisposition to bleeds or to thrombosis.
- •6) Patients who require full-dose anticoagulation.
- •7) Gastrointestinal disorders or abnormalities that would inhibit absorption of the study drug.
- •8) Brain metastases or leptomeningeal disease.
- •9) Treatment with other investigational drugs or participation in another clinical trial within the past four weeks before start of therapy or concomitantly with this trial.
- •10) Chemo-, radio-, or immunotherapy within the past four weeks prior to treatment with the trial drug.
- •11) Patients unable to comply with the protocol.
- •12) Active alcohol or drug abuse.
- •13) Other documented malignancy with the exception of non-melanomatous skin cancer within the past 5 years.
- •14) Patients who are not clinically sterile.
研究者
相似试验
进行中（未招募）
不适用
A study investigating the safety of CVT-301 in patients with Parkinson's DiseaseParkinson's DiseaseEUCTR2012-000181-37-GBCivitas Therapeutics, Inc.24
进行中（未招募）
不适用
A Randomized Phase IIb Placebo-controlled Study of R-ICE Chemotherapy (Rituximab, Ifosfamide, Carboplatin, and Etoposide) with and without SGN-40 (anti-CD40 humanized monoclonal antibody) for Second-line Treatment of Patients with Diffuse Large B-Cell Lymphoma (DLBCL) - NDEUCTR2007-002917-38-ITSEATTLE GENETICS INC.224
进行中（未招募）
不适用
A study for Subjects with Advanced Non-Small Cell Lung Cancer cured with either Tamibarotene or placebo plus Paclitaxel and Carboplatin as First Line Treatment.Advanced Non-Small Cell Lung CancerMedDRA version: 14.1Level: LLTClassification code 10025054Term: Lung cancer non-small cell stage IIIBSystem Organ Class: 100000004864MedDRA version: 14.1Level: LLTClassification code 10025055Term: Lung cancer non-small cell stage IVSystem Organ Class: 100000004864EUCTR2011-004982-33-BGCytRx Corporation140
招募中
2 期
A Phase 2b study with study drug and carboplatin and paclitaxel for Subjects with Advanced Non-Small Cell Lung CancerCTRI/2012/02/002410Daniel Levitt140
进行中（未招募）
1 期
A Phase 2 study to evaluate safety and efficacy of Evinacumab in patients with severe hypertriglyceridemia at risk for acute pancreatitis.Severe Hypertriglyceridemia (sHTG)MedDRA version: 20.1Level: LLTClassification code 10020870Term: HypertriglyceridemiaSystem Organ Class: 100000004861EUCTR2016-003307-62-GBRegeneron Pharmaceuticals, Inc.50